Abstract
As the competition is getting more intense, the number of instances of companies alleged to have been involved in illegal and unethical practices is increasing at an alarming rate. Being an integral part of the society, business organizations have certain duties, responsibilities, and obligations toward the society, referred to as "Business Ethics". The pressures of the reality challenges the ethical frameworks traditionally followed by organizations. The global pharmaceutical industry is highly regulated, capital intensive, and driven by large research and development expenditures. Despite the pharmaceutical industry’s notable contributions to human progress, it is fraught with ethical challenges. This paper presents the ethically practiced unethical strategies that are followed in the industry referencing the case studies of mega corporations and concludes the need for “systematic training in ethics” for all the stakeholders and the need for ethical leadership in an organization.
Publisher
Granthaalayah Publications and Printers
Reference41 articles.
1. Bero LA,Rennie D (1996). Influences on the quality of published drug studies. International Journal Technical Assessment Health Care, 12: 209–37.
2. Blumenthal D (2004). Doctors and Drug Companies. New England Journal of Medicine, 351(18):1885-1890
3. Callaham M (2002). Journal prestige, publication bias, and other characteristics associated with citation of published studies in peer-reviewed journals. JAMA. 287:2847–2850.
4. Davidson RA (1986). Source of funding and outcome of clinical trials. J Gen Intern Med.1:155–158.
5. Dickersin K (1990). The existence of publication bias and risk factors for its occurrence. JAMA. 263:1385–1389
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献